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Mycobacterium tuberculosis uses the ESX-1 secre-
tion system to deliver virulence proteins during infec-
tion of host cells. Here we report a mechanism of
posttranscriptional control of ESX-1 mediated by
MycP1, a M. tuberculosis serine protease. We show
that MycP1 is required for ESX-1 secretion but that,
unexpectedly, genetic inactivation of MycP1 pro-
tease activity increases secretion of ESX-1 sub-
strates. We demonstrate that EspB, an ESX-1 sub-
strate required for secretion, is a target of MycP1
in vitro and in vivo. During macrophage infection,
an inactive MycP1 protease mutant causes hyperac-
tivation of ESX-1-stimulated innate signaling path-
ways. MycP1 is required for growth in mice during
acute infection, while loss of its protease activity
leads to attenuated virulence during chronic infec-
tion. As the key ESX-1 substrates ESAT-6 and
CFP-10 are highly immunogenic, fine-tuning of their
secretion by MycP1 may balance virulence and
immune detection and be essential for successful
maintenance of long-term M. tuberculosis infection.
INTRODUCTION
Mycobacterium tuberculosis, the causative agent of human
tuberculosis, infects two billion people, causing two million
deaths every year (Hingley-Wilson et al., 2003). One reason for
its success as a pathogen is its ability to manipulate its environ-
ment by exporting molecules that allow it to evade or control host
immune responses. A key M. tuberculosis virulence determinant
is the ‘‘type VII’’ ESX-1 secretion system, which transports
protein virulence factors into host cells (Stanley et al., 2003;
Lewis et al., 2003; Guinn et al., 2004; Abdallah et al., 2007).
ESX-1 secretion is required for early replication and full virulence
in macrophages and mice, and has multiple effects on host cells.
The identity of all ESX-1 substrates and the mechanism by
which they affect host cells are not well understood. Various210 Cell Host & Microbe 7, 210–220, March 18, 2010 ª2010 Elsevieractivities have been ascribed to the ESX-1 substrates ESAT-6
and CFP-10, encoded by the genes esxA and esxB, including
inhibition of phagosome maturation and cytokine signaling by
infected macrophages (Stanley et al., 2003; Hsu et al., 2003;
Pathak et al., 2007), interaction with the macrophage immune
receptor TLR2 and inhibition of TLR signaling (Pathak et al.,
2007), and formation of pores in mycobacterial phagosomes,
perhaps allowing bacterial spread (Hsu et al., 2003; Smith
et al., 2008). ESX-1 is clearly implicated in early stages of infec-
tion, including activation of the cytosolic signaling response
(Weiden et al., 2000; Giacomini et al., 2001; Lewinsohn et al.,
2006; O’Riordan et al., 2002). Gene targets of this signaling
pathway include type I IFNs, which function in antiviral defense,
regulation of the immune response, control of cell growth, and
modulation of apoptosis (Taki, 2002). Importantly, type I IFN
induction is dependent on the ESX-1 secretion system (Stanley
et al., 2007). M. tuberculosis elicits type I IFN production via
an as-yet-unidentified receptor, leading to phosphorylation of
the IFN regulatory factor 3 (IRF-3) transcription activator, which
then promotes transcription of genes such as IFN-b and inter-
feron-induced protein with tetratricopeptide repeats 1 (IFIT1).
Studies in M. tuberculosis and related mycobacteria have
identified components and substrates of the ESX-1 system.
The proteins EccCa1 (Rv3870), EccCb1 (Rv3871), and EccD1
(Rv3877) are essential for ESX-1 secretion in M. tuberculosis,
while in M. smegmatis homologs of the proteins EspG
(Rv3866), EccB (Rv3869), EccE1 (Rv3882c), and MycP1 are
also required (Figure 1A; Stanley et al., 2003; Guinn et al.,
2004; Hsu et al., 2003; Converse and Cox, 2005; Bitter et al.,
2009). The machine components are predicted to be either
cytosolic or membrane-bound and to interact with each other,
but are not themselves secreted. However, specific roles for
individual components of the ESX-1 system machinery have
not been characterized. In addition to ESAT-6 and CFP-10,
four other substrates of the ESX-1 system are known: EspA,
EspB, EspC, and EspR (Fortune et al., 2005; MacGurn et al.,
2005; McLaughlin et al., 2007; Gao et al., 2004; Xu et al., 2007;
Raghavan et al., 2008; J.A. MacGurn and J.S.C., unpublished
data). An unusual feature that distinguishes ESX-1 from other
systems is that secretion of all substrates is mutually dependent.
For example, secretion of EspA is blocked in an ESAT-6 mutant,
and vice versa (Fortune et al., 2005).Inc.
Figure 1. M. tuberculosis andM. smegmatis
DmycP1 Mutants Fail to Secrete ESAT-6
(A) Schematic representation of ESX-1 locus in
M. tuberculosis and M. smegmatis.
(B) Diagram of M. tuberculosis MycP1 showing
domains and active site residues D90, H131, and
S332.
(C) Pellets (P) and cell culture supernatants (S)
were generated from indicated strains, and
ESAT-6, GroEL, and KatG were detected by
western blot. GroEL and KatG served as lysis
controls. See Figure S1 for a description of the
M. tuberculosis DmycP1 strain construction.
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immunogenic T cell antigen (Brandt et al., 2000; Colangeli
et al., 2000; Coler et al., 2001; Dietrich et al., 2006). Restoration
of ESAT-6 secretion to the M. bovis BCG vaccine strain, which
lacks the ESX-1 system, conferred enhanced protection against
M. tuberculosis challenge but also increased virulence (Pym
et al., 2003). Thus, while ESAT-6 is an important virulence factor,
it also works against M. tuberculosis infection by stimulating
the immune response. Thus it may be essential for M. tubercu-
losis to tightly regulate the amount of ESAT-6 being exported
in order to maintain an optimal balance between virulence and
immunogenicity. ESX-1 is under the transcriptional control of
EspR, a DNA-binding protein that promotes transcription of
the genes encoding EspA and EspC (Raghavan et al., 2008).
This system is under negative feedback control as EspR is
also secreted via the ESX-1 system, leading to downregulation
of espA and espC transcription. In addition, the regulatory pro-
tein PhoP promotes transcription of espA, espC and Rv3614-
3612c, thus affecting ESX-1 secretion (Frigui et al., 2008;
Gonzalo-Asensio et al., 2008).
There are clues that indicate another potential control mecha-
nism involving the ESX-1 substrate EspB. Upon secretion, EspB
is cleaved near its C terminus, but the protease responsible for
the cleavage is unknown (McLaughlin et al., 2007; Xu et al.,
2007). Western blotting experiments detected EspB as a 61
kDa band in cell lysates but a 50 kDa band in secreted fractions,
while the C-terminal 11 kDa band appeared to be unstable and
was not detected (Xu et al., 2007). The EspB C terminus is
dispensable for its own secretion, as expression of a truncated
form of EspB in an espB transposon mutant led to normal secre-
tion of EspB. However, the C terminus is essential for interaction
of EspB with ESAT-6, maintenance of intracellular levels of
ESAT-6, and secretion of ESAT-6 and CFP-10, suggesting thatCell Host & Microbe 7, 210–22cleavage of EspB could have a regulatory
function in ESX-1 secretion (Xu et al.,
2007).
Given that EspB is processed, it is
notable that one component of the ESX-1
secretion machine, MycP1, is a putative
subtilisin-like serine protease (Brown
et al., 2000; Dave et al., 2002). Bacterial
subtilases are typically secreted and
degrade proteins nonspecifically to pro-
vide cells with readily importable pep-tides (Gupta et al., 2002). In contrast, eukaryotic subtilases
typically cleave substrates after specific basic residues: for
instance, yeast Kex2p is required for certain proteolytic process-
ing steps during the biogenesis of the a mating pheromone
(Bergeron et al., 2000; Julius et al., 1984). MycP1 has not been
extensively studied but is likely important for ESX-1 secretion
as, like other system components, it is encoded by a gene
located within the ESX-1 locus (Figure 1A; Gey Van Pittius
et al., 2001). MycP1 localizes to the cell wall/membrane fraction
and is expressed constitutively during growth in culture, but not
in the vaccine strain M. bovis BCG (Brown et al., 2000; Dave
et al., 2002). It has been reported that MycP1 expression is
increased during growth in macrophages, and its M. leprae
homolog is transcribed during human infection (Brown et al.,
2000; Ribeiro-Guimara˜es et al., 2007).
In this work, we show that MycP1 is essential for ESX-1 func-
tion in M. tuberculosis and is required for early replication in
macrophages and full virulence in mice. Surprisingly, MycP1
plays a dual role in regulating secretion activity of the ESX-1
system. Whereas the MycP1 protein is required for secretion,
abolition of MycP1 protease activity by mutagenesis of the active
site leads to increased secretion. The increase in abundance of
ESX-1 substrates is sensed by infected macrophages, which
induce a heightened cytosolic surveillance response. We find
that, unusually for bacterial subtilases, MycP1 has a defined
substrate specificity and cleaves substrates following proline
residues. In addition, we identify EspB as a substrate of
MycP1. We conclude that the MycP1 protein is required for
ESX-1 secretion but that its protease activity negatively regu-
lates secretion via EspB, a protein substrate that is required
for the function of the ESX-1 system. Identification of a second
level of regulation of the ESX-1 secretion system supports
the notion that M. tuberculosis has evolved remarkably tight0, March 18, 2010 ª2010 Elsevier Inc. 211
Figure 2. Purification and Substrate Speci-
ficity Profiling of M. smegmatis MycP1
(A) MBP-MycP1 (lane 1) and active MycP1 (lane 2)
were purified using amylose and hydroxyapa-
tite affinity chromatography, respectively, and
resolved by SDS-PAGE.
(B) MycP1 protease activity was measured
against fluorogenic tetrapeptide substrate pools,
in each of which the amino acid at one position
was held constant while the other positions were
varied. The x axis indicates which amino acid
was held constant (nl = norleucine), while the
y axis shows activity plotted relative to the highest
activity of the library.
(C) Activity of MycP1 against individual fluorogenic
dipeptide substrates, in the absence or presence
of specific inhibitor.
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mechanisms.
RESULTS
MycP1 Is Required for ESX-1 Secretion
in M. tuberculosis
To determine the role of MycP1 in ESX-1 secretion, we created
a mycP1 deletion mutant in M. tuberculosis via homologous
recombination and verified that the deletion had occurred using
Southern blot analysis (see Figure S1 available online). To test
if MycP1 is required for ESAT-6 secretion, we probed filtered
culture supernatants from exponentially growing wild-type,
DmycP1, EccD1::Tn, and DesxA M. tuberculosis strains using
ESAT-6-specific antibodies. We observed that ESAT-6 was
present in supernatants of wild-type M. tuberculosis but not in
the DmycP1 mutant, a phenotype identical to that of the known
ESX-1 mutant, EccD1::Tn (Figure 1C). ESAT-6 was present in
extracts from cell pellets of all three strains and, as expected,
no ESAT-6 was detectable in the DesxA mutant cells. We also212 Cell Host & Microbe 7, 210–220, March 18, 2010 ª2010 Elsevier Inc.confirmed that wild-type M. smegmatis
secretes ESAT-6 but the DmycP1ms
mutant does not (Figure 1C). Thus,
MycP1 is required for ESX-1 secretion.
Purification, Protease Activity,
and Substrate Specificity Profiling
of MycP1
Analysis of the amino acid sequence of
MycP1 suggests that it is a member of
the subtilase class of serine proteases
(Brown et al., 2000; Dave et al., 2002).
MycP1 contains an N-terminal Sec signal
sequence and a C-terminal transmem-
brane domain, and protein topology
prediction programs (TMHMM, PSORTb)
suggest that it is likely anchored in the cell
membrane with its active site in the
extracytoplasmic space (Sonnhammer
et al., 1998; Gardy et al., 2005). In addi-
tion, MycP1 has a putative propeptideand a catalytic triad of Asp, His, and Ser residues, all hallmarks
of the subtilase family (Figure 1B).
To determine whether MycP1 has protease activity, we
expressed the portion of M. smegmatis MycP1ms containing its
propeptide and protease domain as an MBP fusion protein in
E. coli and purified it using amylose affinity chromatography
(Figure 2A, lane 1). The fusion protein also contained a cleavage
site for the protease Factor Xa between MBP and the MycP1ms
propeptide, allowing removal of MBP. Subtilases are known to
require their propeptides for correct folding, with subsequent
removal of the propeptide by the protease domain, resulting
in an active protease (Fu et al., 2000). Though the Factor
Xa-cleaved MycP1ms propeptide-protease domain fusion was
initially inactive, prolonged incubation with the protease led to
cleavage at a site between the MycP1ms propeptide and pro-
tease domain, removing the propeptide and activating MycP1ms.
We activated subsequent preparations of MBP- MycP1ms
by incubating with active MycP1ms, and purified active
MycP1ms using hydroxyapatite affinity chromatography (Fig-
ure 2A, lane 2).
Figure 3. Protease Activity of MycP1 Nega-
tively Regulates ESX-1 Secretion
(A) MycP1 protease activity was measured against
the Z-GP-AMC substrate. Activity of protease-
inactive MycP1 (MycP1 S334A) is expressed rela-
tive to wild-type MycP1.
(B) Western blot detection of ESAT-6, MycP1-HA,
and KatG inM. smegmatis pellets (P) and superna-
tants (S) from wild-type and mutant strains.
(C) Western blot detection of ESAT-6, CFP-10,
EspA, EspR, GroEL, and Mpt32 in M. tuberculosis
pellets (P) and supernatants (S) from wild-type and
mutant cells. See Figure S2 for data showing that
the DmycP1 mutation did not exert a polar effect
on transcription of the downstream gene, eccE1.
(D) Quantitation of ESAT6 in M. tuberculosis
supernatants from wild-type and mutant strains,
expressed relative to Sec-dependent substrate
Mpt32.
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tested its activity against a positional scanning synthetic com-
binatorial library, which comprised tetrapeptides of every pos-
sible amino acid composition (Choe et al., 2006). We found
that MycP1ms had activity against a wide variety of substrates
with different amino acids in the P1 position but has an unusual
preference for proline at this site (Figure 2B). MycP1ms shows
greater promiscuity in the P2-P4 positions, though there is a pref-
erence for small hydrophobic amino acids such as alanine and
leucine at these sites. The preference of MycP1ms for proline
at P1 was confirmed using individual substrates (Figure 2C).
Although the degeneracy of the MycP1sm recognition sequence
made it difficult to find potential substrates with this information
alone, these results allowed us to design a specific substrate,
Z-Gly-Pro-AMC, and a specific phosphonate inhibitor, Z-Gly-
Pro-(OPh)2, which completely abrogated the activity of MycP1ms
in vitro (Figure 2C).
Protease Activity of MycP1 Negatively Regulates ESX-1
Secretion
Since the DmycP1 strain failed to secrete ESAT-6, we reasoned
that protease activity would also be required for MycP1 function
and ESX-1 secretion. To begin to determine the role of MycP1
protease activity, we expressed and purified a protease mutant
(MycP1ms S334A) in which the active site serine codon in
M. smegmatis mycP1ms was replaced with an alanine codon
using site-directed mutagenesis. Recombinant MycP1ms S334A
had no significant activity against Z-Gly-Pro-AMC (Figure 3A).
We then examined ESAT-6 secretion in M. smegmatis
DmycP1sm bacteria expressing either wild-type MycP1ms or
MycP1ms S334A. Expression of wild-type MycP1ms inDmycP1msCell Host & Microbe 7, 210–22cells restored ESAT-6 secretion, although
not to wild-type levels. Surprisingly,
despite the fact that MycP1ms is essential
for secretion, expression of MycP1ms
S334A significantly increased ESAT-6
secretion above wild-type levels (Fig-
ure 3B). We observed identical results
when we expressed a different activesite mutant (D92A, data not shown) of MycP1sm in DmycP1ms
cells, indicating that the phenotype is the direct result of the
loss of proteolytic activity.
We observed a similar phenotype in M. tuberculosis, in which
expression of inactive MycP1 (MycP1 S332A) led to increased
secretion of ESAT-6 (Figure 3C). In M. tuberculosis we comple-
mented the DmycP1 strain with wild-type or inactive MycP1
in an operon with the downstream gene, EccE1, to achieve
complete complementation (Roback et al., 2007; see the
Supplemental Experimental Procedures and Figure S2). In addi-
tion to ESAT-6, secretion of other known ESX-1 substrates—
CFP-10, EspA, and EspR—was also increased relative to wild-
type. However, Mpt32, a substrate of the Sec pathway that is
exported independently of ESX-1, was secreted to equal levels
in all strains, demonstrating that the MycP1 mutant specifically
modulates ESX-1 secretion (Figure 3C). Expression of wild-
type MycP1 restored ESAT-6 secretion nearly to levels observed
in wild-type M. tuberculosis. Since the difference in ESAT-6
secretion observed between DmycP1-expressing wild-type
MycP1 versus MycP1 S332A was not as robust in M. tubercu-
losis as in M. smegmatis, we further examined ESAT-6 in culture
supernatants by quantitative western blotting. Using this tech-
nique we determined that the amount of ESAT-6 relative to
Mpt32 in culture supernatants was approximately 2-fold greater
in the MycP1 S332A strain than the wild-type strain (Figure 3D).
Therefore, the MycP1 protein is required for ESX-1 secretion, but
its protease activity inhibits the system.
MycP1 Cleaves EspB, an ESX-1 Substrate
We were curious to understand the mechanism by which MycP1
proteolysis negatively regulates protein secretion. Since MycP10, March 18, 2010 ª2010 Elsevier Inc. 213
Figure 4. MycP1 Directly Cleaves EspB,
an ESX-1 Substrate
(A) Western blot detection of EspB in M. tubercu-
losis pellets (P) and supernatants (S) from wild-
type and mutant strains. The same samples were
run on a standard 133 8 cm gel (W3 L, top panel)
and a higher-resolution 16 3 16 cm gel (bottom
panel) to reveal the different cleaved forms of
EspB.
(B) In vitro cleavage assay of MBP-EspB (top
panel) and BSA (bottom panel) by WT MycP1,
MycP1 S332A, and WT MycP1 in the presence
of specific inhibitor.
(C) Schematic representation of EspB showing
cleavage sites and the region used to generate
the EspB antibody. See Figure S3 for MS results
used to identify the EspB cleavage products.
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is that MycP1 self-proteolysis leads to its degradation, thus
controlling ESX-1 secretion. However, quantitative western
blotting showed that the levels of wild-type and S332A mutant
MycP1 were equivalent and that the half-lives of the proteins
were also identical (data not shown).
An alternative hypothesis is that MycP1 cleaves an activator of
ESX-1 secretion. A likely candidate is EspB (Rv3881c), which is
secreted in an ESX-1-dependent manner and is required for
the function of the ESX-1 system (McLaughlin et al., 2007; Gao
et al., 2004; Xu et al., 2007). EspB accumulates in culture super-
natants in an apparent proteolytically processed form, though
the protease responsible has not been identified (McLaughlin
et al., 2007). Furthermore, previous work has suggested that
cleavage of EspB occurs after proline 332 (Xu et al., 2007),
a result consistent with our substrate specificity profiling results.
We therefore used an antibody specific for EspB to test whether
cleavage requires MycP1 in vivo. This antibody recognizes a 100
residue fragment of EspB comprising amino acids 234–333 and
thus only detects full-length protein and the N-terminal cleavage
products (Figure 4C; McLaughlin et al., 2007). Full-length EspB
(460 amino acids) was present in whole-cell lysates of all strains
(Figure 4A, lanes 1–4). We observed that EspB was secreted in
its cleaved form by wild-type M. tuberculosis (Figure 4A, lane
5) and by M. tuberculosis DmycP1 cells expressing wild-type
MycP1 (Figure 4A, lane 7), but was not secreted by the DmycP1
mutant (Figure 4A, lane 6). However, full-length EspB was
secreted from the MycP1 S332A strain (Figure 4A, lane 8),
consistent with the prediction that MycP1 directly cleaves
EspB. We also observed that a fraction of the secreted EspB
was still processed into a low molecular weight form. Using
a higher-resolution gel, we observed that the original EspB
band in secreted fractions of wild-type cells and the comple-
mented strain resolved into three different EspB cleavage prod-
ucts (Figure 4A, lower panel, lanes 5 and 7), implying that EspB is
cleaved at a minimum of three sites during secretion. Impor-
tantly, two of the three cleavage products were absent in the214 Cell Host & Microbe 7, 210–220, March 18, 2010 ª2010 Elseviersupernatant of the MycP1 S332A strain, while full-length EspB
was detected (Figure 4A, lane 8). This suggests that MycP1 is
responsible for cleaving EspB at two sites.
To determine whether MycP1 directly cleaves EspB, recombi-
nant EspB was subjected to in vitro cleavage by MycP1sm. Wild-
type MycP1sm efficiently cleaved EspB but not the specificity
control protein BSA (Figure 4B). However, neither protease-
dead MycP1sm nor wild-type MycP1sm treated with Z-Gly-Pro-
(OPh)2 inhibitor could cleave EspB, indicating that EspB is
a proteolytic substrate of MycP1.
To identify the sites at which EspB is cleaved in vivo, we used
mass spectroscopy to determine the exact molecular weight of
cleaved EspB purified from M. tuberculosis-secreted protein
fractions (Figure S3). Although we were unable to identify the
Pro332 cleaved form, we identified Ala392 as a second cleavage
site. Our substrate specificity profiling studies indicated that
Ala is tolerated at this site, though not most preferred. Based
on the sizes of the fragments on the SDS-PAGE gel (Figure 4A,
lane 5), it is likely that the top band represents the Ala392 product
and the middle band the Pro332 fragment, both of which are
dependent on MycP1.
To study the role of EspB cleavage by MycP1, we created
Ala392Ser and Pro332Ala mutant alleles of espB by site-directed
mutagenesis (Figure 4C). Unfortunately, repeated attempts to
transform either wild-type M. tuberculosis or an M. marinum
espB::Tn mutant strain with integrating and episomal vectors
expressing these mutants yielded extremely poor transformation
efficiencies, indicating that these mutations were toxic to the
cells.
Effects of Increased ESX-1 Secretion during
Macrophage Infection
Since fine control of virulence factors is important for bacterial
pathogens, we sought to determine if increased secretion
of ESX-1 substrates in the MycP1 S332A mutant impacts
M. tuberculosis virulence. Since ESX-1 is required for stimulating
innate immune responses, we tested whether ESX-1Inc.
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responses. In macrophages and dendritic cells, M. tuberculosis
induces the cytosolic surveillance response, characterized by
the transcription of IRF-3-responsive genes such as IFN-b and
IFIT-1, in an ESX-1-dependent manner (Stanley et al., 2007;
Lewinsohn et al., 2006). We infected murine bone marrow-
derived macrophages with wild-type, DmycP1, complemented,
and MycP1 S332A strains; extracted macrophage RNA; and
quantified IFN-b and IFIT-1 mRNA expression using quantitative
real-time PCR. As expected, wild-type bacteria elicited a strong
cytosolic response, but DmycP1 mutant cells induced the
pathway poorly. Importantly, the MycP1 S332A strain induced
the cytosolic response more robustly than wild-type (Figures
5A and 5B). These data indicate that the MycP1 S332A strain
has hyperactivated ESX-1 secretion during macrophage infec-
tion, resulting in increased innate immune signaling.
As ESX-1 is required for growth in macrophages and mice, we
postulated that the enhanced secretion of ESX-1 substrates in
the MycP1 S332A strain might alter the course or outcome of
a M. tuberculosis macrophage infection (Stanley et al., 2003).
We found that DmycP1 bacilli are attenuated for intracellular
growth as compared to wild-type bacteria, consistent with other
ESX-1 mutants such as EccD1::Tn, which also shows an initial
drop in bacterial CFU followed by some restoration of bacterial
loads, although never to the level of wild-type bacteria (Stanley
et al., 2003). However, expression of wild-type or inactive
MycP1 in the DmycP1 mutant strain restored growth to wild-
type levels (Figure 5C). Thus, although innate immune signaling
is hyperactivated by the MycP1 S332A strain, its effects do not
alter M. tuberculosis replication in macrophages ex vivo.
Virulence ofmycP1 Mutants in Mice
To test the role of MycP1 in pathogenesis in vivo, we infected
mice via the aerosol route with wild-type, DmycP1, comple-
mented, and MycP1 S332A bacteria. Wild-type, complemented,
and MycP1 S332A bacteria grew normally during the acute
stages of infection, leading to a 100-fold increase in colony-
forming units (cfus) in mouse lungs within 7 days and a 10,000-
fold increase within 21 days postinfection (Figure 5D). In con-
trast, DmycP1 mutant cells replicated poorly, leading to CFU
levels 10-fold lower than the other strains at days 7 and 21.
Similar phenotypes have been observed with other ESX-1
mutants such as EccD1::Tn and DesxA, which are also attenu-
ated for growth at these time points (Stanley et al., 2003). The
attenuation of the DmycP1 strain was even more pronounced
in spleens (Figure 5E) and livers (Figure 5F), in which DmycP1
bacterial CFUs were 100-fold lower than those from wild-type,
complemented, and MycP1 S332A bacteria 21 days postinfec-
tion. Survival curves indicated that all of the mice infected with
wild-type M. tuberculosis succumbed to infection by 300 days
postinfection, while none of the mice infected with DmycP1
mutant bacteria succumbed to infection during that time
(Figure 5G). Mice infected with the complemented strain also
succumbed to infection, though with slightly slower kinetics
than those infected with wild-type bacteria, consistent with the
partial restoration of ESX-1 secretion observed in secretion
assays. Interestingly, mice infected with MycP1 S332A bacteria
showed similar survival rates as those infected with DmycP1
cells, with all surviving over the course of the experiment withCell Hothe exception of one that succumbed very early, most likely to
nontuberculous disease. When sections of infected mouse
lungs harvested 56 days postinfection were examined, it was
apparent that the MycP1 S332A strain elicited a more muted
inflammatory response than the wild-type and complemented
strains, giving rise to histopathological lesions that resembled
those induced byDmycP1 cells (Figure 5H and Figure S4). There-
fore, the MycP1 protein, like other ESX-1 components, is critical
during the acute stages of infection and required for growth.
While the regulation of ESX-1 secretion by MycP1 protease
activity is dispensable for the early growth of the bacterium, it
is important for immunopathology and virulence during the
chronic stage of infection.
DISCUSSION
We have discovered that MycP1 is not only an obligatory compo-
nent of the ESX-1 secretion system but that this protease plays
an unexpected dual role in controlling protein export. In partic-
ular, ESX-1 secretion is abolished in the absence of MycP1,
but loss of MycP1 protease activity leads to enhanced secretion
of ESX-1 substrates. How would protease activity modulate
ESX-1 secretion? The identification of EspB, which itself is
required for ESX-1 secretion, as a direct MycP1 substrate sug-
gests a model in which full-length EspB functions in the periplas-
mic space to promote secretion but its proteolysis serves to limit
secretion of other ESX-1 substrates (Figure 6). Since EspB cleav-
age products are absent from M. tuberculosis cell lysates,
EspB is likely secreted as a full-length protein into the peri-
plasm, where it is proteolyzed by MycP1, thus turning off secre-
tion. This is consistent with our data showing that in the MycP1
S332A mutant, full-length EspB accumulates and ESX-1 secre-
tion increases. Although its mechanism of action is unknown,
full-length EspB could serve as a limiting component of the
secretion pore, through which other ESX-1 substrates subse-
quently pass. Why does removal of MycP1 abolish secretion?
We speculate that MycP1 interacts with multiple ESX-1 machine
components and thus is required for complex formation, though
other possibilities certainly exist. Examples of such positive and
negative regulation of a pathway by a single protein are unusual
in biology.
We found that EspB is proteolyzed at at least three sites, two
of which (Pro332, Ala392) require MycP1. Both of these sites are
consistent with our in vitro profiling studies. The protease
responsible for cleaving EspB at the third site has not been iden-
tified. However, the M. tuberculosis genome contains four
homologs of MycP1, each associated with a duplication of the
ESX-1 secretion system, whereas no homologs of EspB exist
(Gey Van Pittius et al., 2001). One of these MycP1 homologs
may proteolyze EspB at the third site. The combination of
genetics and profiling has been important to understand the
molecular details of MycP1 function.
Although the ESX-1 system is a key virulence determinant of
M. tuberculosis, its exact role in virulence has not yet been eluci-
dated. One consequence of ESX-1 secretion is that it stimulates
a unique cytosolic surveillance pathway, perhaps utilizing the
pore-forming activity of ESAT-6 to allow substrates to escape
from the macrophage phagosome into the cytosol (Stanley
et al., 2007; Weiden et al., 2000; Giacomini et al., 2001;st & Microbe 7, 210–220, March 18, 2010 ª2010 Elsevier Inc. 215
Figure 5. Oversecretion of ESAT-6 by DmycP1 + MycP1 S332A Mutant Is Sensed by Macrophages, and MycP1 Is Required for Virulence in
Macrophages and Mice
Bone marrow-derived macrophages were infected with wild-type and mutant strains of M. tuberculosis. At indicated time points, total RNA was harvested from
macrophage monolayers, and IFN-b (A) and IFIT-1 (B) mRNA levels were measured by quantitative PCR. Values were normalized to actin mRNA levels and repre-
sent the mean ± SD of three independent experiments, each performed in triplicate. (C) Macrophages were infected and lysed at the indicated time points, and
bacterial CFUs were enumerated by plating. Values represent the mean ± SD of three independent experiments, each performed in triplicate. (D) BALB/c mice
were infected with 102 CFU of each strain by aerosol, and bacteria were isolated from lungs immediately following infection, as well as at 7 and 21 days
postinfection. Five mice were used per time point, and asterisks indicate significant differences by Kruskal-Wallis test. CFUs were also obtained from spleens
(E) and livers (F) of infected mice at 21 days postinfection. (G) Survival of infected BALB/c mice (n = 5 per group). Statistical analysis indicated significant differ-
ences between all four strains (p < 0.05) and more subtle differences between DmycP1 + WT MycP1 and DmycP1 + MycP1 S332A strains (p < 0.13).
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Figure 6. Model of MycP1-Mediated Regulation of the ESX-1 Secre-
tion System in M. tuberculosis
In wild-typeM. tuberculosis, MycP1 is part of a complex and proteolyzes EspB
in the periplasm. Full-length EspB is an activator of ESX-1 secretion, and its
cleavage functions to inhibit secretion. In DmycP1 + MycP1 S332A cells,
full-length EspB accumulates and therefore ESX-1 secretion is hyperactivated.
In DmycP1 bacteria, secretion is abolished because the secretion complex
fails to assemble in the absence of MycP1.
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of this signal transduction pathway in antibacterial defense is
unclear, the gene targets include a number of immunomodula-
tory molecules, including type I IFNs (Weiden et al., 2000; Giaco-
mini et al., 2001). It is therefore suggestive that increased activity
of ESX-1 may overstimulate the cytosolic surveillance response,
tipping the balance between bacterium and host control. Indeed,
infection of macrophages with the MycP1 S332A mutant led to
increased IFN-b production, and mice infected with these
bacteria displayed an altered inflammatory response.
Given that ESX-1 is under fine transcriptional control by EspR
(Raghavan et al., 2008), it is curious that M. tuberculosis has
evolved an additional layer of regulation mediated by MycP1.
Whereas EspR activity is required for inducing the system, irre-(H) Hematoxylin/eosin-stained lung sections of mice infected with indicated strains
DmycP1 + WT MycP1 bacteria showed numerous consolidated granulomas (arro
strains showed fewer granulomas and more alveolar space. See Figures S4A and
Cell Hoversible proteolysis by MycP1 may allow the bacillus to termi-
nate secretion rapidly and completely. Further, the periplasmic
location of MycP1 would allow the bacterium to sense and
respond to changes in the environment. Although we do not
understand the details of the overlap between transcriptional
and posttranscriptional control of ESX-1 secretion, it is clear
that the regulation mediated by MycP1 is important during
infection.
A compelling rationale for why tight control of ESX-1 secretion
is important for M. tuberculosis infection is that its key sub-
strates, ESAT-6 and CFP-10, are both essential for virulence
as well as highly immunogenic (Brandt et al., 2000; Colangeli
et al., 2000; Coler et al., 2001; Dietrich et al., 2006). In particular,
ESAT-6 is a highly protective antigen in experimentally infected
animals (Pym et al., 2003). Thus it is possible thatM. tuberculosis
regulates the quantity and/or timing of ESAT-6 export in order
to achieve an optimal balance between promoting its own viru-
lence and stimulating the immune system. The inability of
DmycP1 mutant bacteria to secrete ESAT-6 led to severe atten-
uation in macrophage and mouse models, consistent with
previous reports demonstrating a key role of ESX-1 during the
early phase of infection (Stanley et al., 2003). Although M. tuber-
culosisMycP1 S332A mutant cells grew to similar bacterial loads
as wild-type, survival assays and histopathological analysis
showed that it is attenuated compared to wild-type M. tubercu-
losis. Similar phenotypes have been observed in DsigC, DsigE,
DsigH, and DwhiB mutants of M. tuberculosis (Sun et al., 2004;
Ando et al., 2003; Kaushal et al., 2002; Steyn et al., 2002).
Wild-type bacteria may therefore shut off secretion later during
infection to avoid detection by the immune system. The observa-
tion that the number of ESAT-6-reactive T cells decreases during
chronic M. tuberculosis infection suggests that the bacterium
does indeed shield these antigens from the immune system
(Lazarevic et al., 2005). The constitutive ESAT-6 secretion
caused by inactivation of MycP1 may promote ESAT-6 antigen
presentation by antigen-presenting cells during chronic infec-
tion, priming T cells to generate a stronger immune response
against M. tuberculosis. MycP1 could perhaps be an interesting
drug target for latent M. tuberculosis infection, as it is predicted
to be outside the cell membrane and hence accessible to small
molecules. Perhaps more obviously, if inhibition of MycP1 activ-
ity uncovers hidden, potent antigens during latent infection,
the incorporation of protease-dead MycP1 alleles into current
live attenuated vaccine strains may increase immunogenicity.
EXPERIMENTAL PROCEDURES
A detailed description of all procedures and protocols is available as Supple-
mental Information.
Bacterial Strains, Plasmids, and Culture Conditions
M. smegmatis (mc2155) and M. tuberculosis (Erdman) were grown as
described (Cox et al., 1999). The M. tuberculosis mycP1 deletion mutant
(DmycP1) was constructed by replacing the entire mycP1 open reading frame
with the hygromycin resistance gene by homologous recombination. The dele-
tion plasmid was delivered into M. tuberculosis using specialized phage, as, harvested 56 days postinfection. Lungs from mice infected with wild-type and
ws), while lungs from mice infected with DmycP1 and DmycP1 + MycP1 S332A
S4B for more images and results of our quantitative histopathology analysis.
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by Southern blotting.
Protein Preparation and Analysis
For secretion assays, M. smegmatis and M. tuberculosis were grown in Sau-
ton’s medium as described (Converse and Cox, 2005; Stanley et al., 2003).
Proteins were visualized by immunoblotting using antibodies against ESAT-6
(Assay Designs), HA (Covance), EspA, EspB, EspR, KatG, GroEL, and
Mpt32 (all from Colorado State University; EspA was also the kind gift of
S. Fortune, Harvard University). For quantitative western blots, all incubations
of the nitrocellulose membranes were performed in Odyssey blocking reagent
(LI-COR Biosciences), and infrared (IR) dye-conjugated secondary antibodies
were used. Proteins thus labeled were visualized using the Odyssey IR imaging
system and band density quantitated with the accompanying Odyssey 3.0
software.
Expression and Purification ofWild-Type and Protease-DeadMycP1
The transmembrane regions and topology of MycP1 were analyzed in silico
using the protein prediction programs TMHMM (Sonnhammer et al., 1998)
and PSORTb (Gardy et al., 2005). N-terminally maltose-binding protein
(MBP)-tagged M. smegmatis MycP1ms propeptide and active domain were
expressed in E. coli BL21 codon plus cells. MBP-MycP1ms was purified from
lysed cells using amylose resin (New England Biolabs), yielding approximately
2 mg of purified protein per liter of culture. MBP and the propeptide were
removed by incubating with active MycP1ms and subsequent binding to
40 mM Macro-Prep ceramic hydroxyapatite beads (Bio-Rad). Protease-dead
M. tuberculosis and M. smegmatis MycP1 were generated by replacing the
active site Ser residue (Ser332 and Ser334, respectively) with Ala by site-
directed mutagenesis, using pYO17 (M. tuberculosis) and pSEC82 and
pYO1 (M. smegmatis) as templates.
Protease Activity Assays, Substrate Specificity Profiling,
and Inhibitor Assays
MycP1ms activity assays were performed in 20 mM Tris (pH 8), 100 mM NaCl,
2 mM CaCl2, and 0.01% Brij-35. Substrate specificity was determined using
a library of fluorogenic tetrapeptide substrates, as described earlier (Choe
et al., 2006). Individual activity assays were performed similarly on single
dipeptide substrates diphenyl Na-benzoxycarbonyl-Gly-Pro-amino methyl
coumarin (Z-GP-AMC), Z-Leu-Arg-AMC (Z-LR-AMC), and Suc-Leu-Tyr-AMC
(Suc-LY-AMC) (Bachem). The inhibitor Z-Gly-Pro-phosphonate (Z-GP-
[OPh]2) was chemically synthesized as described previously (Gilmore et al.,
2006).
Expression, Purification, and Cleavage Assay of Recombinant EspB
N-terminally MBP-6x Histidine (His)-tagged M. tuberculosis EspB was
expressed in E. coli BL21 codon plus cells. After cell lysis, MBP-His-EspB
was purified using amylose resin (New England Biolabs) followed by Ni-NTA
agarose resin (QIAGEN), yielding approximately 2 mg of purified protein per
liter of culture. The MBP-His tag was removed by incubating with His-tagged
AcTEV protease (Invitrogen) and subsequent binding to Ni-NTA agarose resin.
EspB was treated with equal quantities of wild-type MycP1ms, protease-dead
MycP1ms, or wild-type MycP1ms plus Z- Gly-Pro-(OPh)2 in MycP1 activity
buffer at room temperature for 10 min. Reactions were stopped by addition
of the serine protease inhibitor phenylmethylsulfonyl fluoride (PMSF) and
SDS-PAGE sample buffer. Proteins were resolved on 4%–20% polyacryl-
amide gels and visualized by Coomassie staining.
Purification of Native EspB, Cleavage Site Identification,
and Characterization of EspB Mutant
An M. tuberculosis strain expressing C-terminally His-FLAG-tagged EspB
under the control of a Tet-inducible promoter was constructed and cultured
in Sauton’s medium as described above. Secreted EspB-His-FLAG was
purified from culture supernatants using anti-FLAG M2 affinity gel (Sigma).
The exact molecular weight of EspB-His-FLAG was determined by liquid chro-
matography mass spectrometry of the intact protein at the Vincent Coates
Foundation Mass Spectrometry Laboratory (Stanford University) and used to
identify the EspB cleavage site.218 Cell Host & Microbe 7, 210–220, March 18, 2010 ª2010 ElsevierMacrophage Infections
All mice were housed under pathogen-free conditions, and all experiments
were conducted using a University of California, San Francisco, Institutional
Animal Care and Use Committee-approved protocol. Bone-marrow-derived
macrophages from C57BL/6 mice were harvested, cultured, and infected as
described (Stanley et al., 2003). Macrophages were infected with M. tubercu-
losis strains at a multiplicity of infection (moi) of 1 for CFU enumeration and an
moi of 10 for RNA extraction.Quantitative Real-Time PCR
Four hours postinfection with M. tuberculosis, macrophage RNA was
extracted as described (Stanley et al., 2007). One microgram of RNA was
reverse-transcribed using the SuperScript III First Strand kit (Invitrogen) with
oligo-dT primers. A 1:20 dilution of the cDNA was used for quantitative real-
time PCR with SYBR Green as label and primers for actin (ACTIN-F and
ACTIN-R), interferon-beta (IFN-b) (IFNb-F and IFNb-R), and interferon-induced
protein with tetratricopeptide repeats 1 (IFIT-1) (IFIT-1F and IFIT-1R).Mouse Infection
BALB/c mice (Jackson Laboratories) were infected by aerosol with 1.5 3 102
cfus as described (Kumar et al., 2007). Lungs were harvested, homogenized,
and plated for CFU at 0, 7, 21, and 56 days postinfection, as described (Cox
et al., 1999; Stanley et al., 2003). Spleens and livers were similarly harvested
and plated at 21 and 56 days postinfection, but not at 0 and 7 days postinfec-
tion, as bacterial loads would be below detection limits. In addition, lungs,
spleens, and livers collected 56 days after infection were sectioned and
stained with hematoxylin and eosin at the Histology Core Laboratory of the
Gladstone Institute. Sections were visualized on an upright Nikon Eclipse
E600 epifluorescence microscope. For survival experiments, infected mice
were sacrificed when they had lost 15% of their maximal body weight. Statis-
tical analysis was performed using the Kruskal-Wallis test for CFU data and the
Kaplan-Meier test for survival data, using GraphPad InStat Software.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, two tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.chom.2010.02.006.ACKNOWLEDGMENTS
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